サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1098530

がん診断の世界市場予測（～2028年）：技術別、用途別、地域別の分析

Cancer Diagnostics Market Forecasts to 2028 - Global Analysis By Technology (Instrument-Based, Platform-Based Diagnostics), Application (Blood Cancer, Breast Cancer, Cervical Cancer), and By Geography
出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.42円
がん診断の世界市場予測（～2028年）：技術別、用途別、地域別の分析
出版日: 2022年07月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん診断の市場規模は、2021年に178億2,000万米ドルとなり、予測期間中に13.5％のCAGRで拡大し、2028年までに432億4,000万米ドルに達すると予測されています。

当レポートでは世界のがん診断市場を調査し、市場の促進要因・抑制要因、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • 技術分析
  • 用途分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界のがん診断市場：技術別

  • 機器ベース
    • 生検
    • リキッドバイオプシー
    • 画像診断
  • プラットフォームベース
    • ポリメラーゼ連鎖反応（PCR）
    • 次世代シーケンシング（NGS）
    • マイクロアレイ
    • インサイチュハイブリダイゼーション（ISH）
    • 免疫組織化学（IHC）
    • フローサイトメトリー
  • 腫瘍バイオマーカー検査
    • アルファフェトプロテイン（AFP）検査
    • アルカリホスファターゼ（ALP）検査
    • 乳がん（BRCA）遺伝子検査
    • CA-19検査
    • がん胎児性抗原）検査
    • 循環腫瘍細胞（CTC）検査
    • EGFR変異試験
    • ヒト上皮成長因子受容体2（HER2）
    • キルステンラット肉腫ウイルス（KRAS）変異試験
    • 前立腺特異抗原（PSA）検査

第6章 世界のがん診断市場：用途別

  • 血液がん
  • 乳がん
  • 子宮頸がん
  • 結腸直腸がん
  • 腎臓がん
  • 肝臓がん
  • 肺がん
  • 黒色腫
  • 卵巣がん
  • 膵臓がん

第7章 世界のがん診断市場：エンドユーザー別

  • 病院関連検査所
  • 診断研究所
  • がん研究機関

第8章 世界のがん診断市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第9章 主な発展

  • 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
  • 買収と合併
  • 新製品の発売
  • 拡張
  • その他の重要な戦略

第10章 企業プロファイル

  • Abbott Diagnostics
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMerieux
  • C.R. Bard, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare (A Subsidiary of General Electric Company)
  • Hologic,Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Qiagen
  • Roche Diagnostics
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.
図表

List of Tables

  • Table 1 Global Cancer Diagnostics Market Outlook, By Region (2020-2028) (US $MN)
  • Table 2 Global Cancer Diagnostics Market Outlook, By Technology (2020-2028) (US $MN)
  • Table 3 Global Cancer Diagnostics Market Outlook, By Instrument-Based (2020-2028) (US $MN)
  • Table 4 Global Cancer Diagnostics Market Outlook, By Biopsies (2020-2028) (US $MN)
  • Table 5 Global Cancer Diagnostics Market Outlook, By Liquid Biopsy (2020-2028) (US $MN)
  • Table 6 Global Cancer Diagnostics Market Outlook, By Diagnostic Imaging (2020-2028) (US $MN)
  • Table 7 Global Cancer Diagnostics Market Outlook, By Platform-Based Diagnostics (2020-2028) (US $MN)
  • Table 8 Global Cancer Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2020-2028) (US $MN)
  • Table 9 Global Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2020-2028) (US $MN)
  • Table 10 Global Cancer Diagnostics Market Outlook, By Microarrays (2020-2028) (US $MN)
  • Table 11 Global Cancer Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2020-2028) (US $MN)
  • Table 12 Global Cancer Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2020-2028) (US $MN)
  • Table 13 Global Cancer Diagnostics Market Outlook, By Flow Cytometry (2020-2028) (US $MN)
  • Table 14 Global Cancer Diagnostics Market Outlook, By Tumor Biomarkers Tests (2020-2028) (US $MN)
  • Table 15 Global Cancer Diagnostics Market Outlook, By Alpha-Fetoprotein (AFP) Tests (2020-2028) (US $MN)
  • Table 16 Global Cancer Diagnostics Market Outlook, By Alkaline Phosphatase (ALP) test (2020-2028) (US $MN)

Table17 Global Cancer Diagnostics Market Outlook, By Breast Cancer (BRCA) Gene Test (2020-2028) (US $MN)

  • Table 18 Global Cancer Diagnostics Market Outlook, By CA-19 Tests (2020-2028) (US $MN)
  • Table 19 Global Cancer Diagnostics Market Outlook, By Carcinoembryonic Antigen) Test (2020-2028) (US $MN)
  • Table 20 Global Cancer Diagnostics Market Outlook, By Circulating Tumor Cell (CTC) Test (2020-2028) (US $MN)
  • Table 21 Global Cancer Diagnostics Market Outlook, By Epidermal Growth Factor Receptor Gene (EGFR) Mutation Tests (2020-2028) (US $MN)
  • Table 22 Global Cancer Diagnostics Market Outlook, By Human Epidermal Growth Factor Rceptor 2 (HER2) (2020-2028) (US $MN)
  • Table 23 Global Cancer Diagnostics Market Outlook, By Kirsten Rat Sarcoma Virus (KRAS) Mutation Tests (2020-2028) (US $MN)
  • Table 24 Global Cancer Diagnostics Market Outlook, By Prostate-Specific Antigen (PSA) Test (2020-2028) (US $MN)
  • Table 25 Global Cancer Diagnostics Market Outlook, By Application (2020-2028) (US $MN)
  • Table 26 Global Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) (US $MN)
  • Table 27 Global Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) (US $MN)
  • Table 28 Global Cancer Diagnostics Market Outlook, By Cervical Cancer (2020-2028) (US $MN)
  • Table 29 Global Cancer Diagnostics Market Outlook, By Colorectal Cancer (2020-2028) (US $MN)
  • Table 30 Global Cancer Diagnostics Market Outlook, By Kidney Cancer (2020-2028) (US $MN)
  • Table 31 Global Cancer Diagnostics Market Outlook, By Liver Cancer (2020-2028) (US $MN)
  • Table 32 Global Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) (US $MN)
  • Table 33 Global Cancer Diagnostics Market Outlook, By Melanoma (2020-2028) (US $MN)
  • Table 34 Global Cancer Diagnostics Market Outlook, By Ovarian Cancer (2020-2028) (US $MN)
  • Table 35 Global Cancer Diagnostics Market Outlook, By Pancreatic Cancer (2020-2028) (US $MN)
  • Table 36 Global Cancer Diagnostics Market Outlook, By End User (2020-2028) (US $MN)
  • Table 37 Global Cancer Diagnostics Market Outlook, By Hospital Associated Labs (2020-2028) (US $MN)
  • Table 38 Global Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2020-2028) (US $MN)
  • Table 39 Global Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2020-2028) (US $MN)

Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC21562

According to Stratistics MRC, the Global Cancer Diagnostics Market is accounted for $17.82 billion in 2021 and is expected to reach $43.24 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Cancer diagnostics is a method of identifying different biomarkers, proteins, and some signs that lead to the identification of the presence of a cancerous tumor. Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease, and schedule & review treatment outcomes. Diagnostic procedures for cancer may include imaging, tumor biopsy, laboratory tests (including tests for tumor markers), endoscopic examination, surgery, or genetic testing.

Market Dynamics:

Driver:

Development in the number of private diagnostic centers

The number of private diagnostic centers is rising across the globe as there is a rising demand for diagnostic imaging procedures and an increasing burden on public hospitals owing to the limited number of imaging modalities at their disposal. Favorable healthcare policies, coupled with high per capita healthcare spending, have created a conducive environment for the adoption of advanced cancer diagnostic technologies such as imaging. Strategies undertaken by these companies include product launches and expansion plans, which will drive market growth.

Restraint:

High cost

The rising demand for tests coupled with technological advancements with faster results and accuracy has escalated the price associated with imaging cancer diagnostics. The practice of imaging diagnostics has grown exponentially over the last decade in the industry. Though, in numerous countries, it is observed that some cancer diagnostic services are not fully covered by insurance.

Opportunity:

Recommendations for cancer screening, Introduction of novel diagnostic biomarkers

The identification of prospective cancer biomarkers has been made possible by technological developments in the field of biotechnology, and some of these biomarkers have been marketed. The introduction of novel diagnostic biomarkers is creating lucrative opportunities for the growth of the market. Moreover, to detect cancer in the early stages and bring down the mortality rate, governments in advanced countries and primary care doctors are recommending cancer screening tests for patients. The increased understanding of certain cancer biomarkers is creating a huge commercial opportunity for treating cancer patients through improved detection technology and equipment.

Threat:

Insufficient reimbursement policies

Inadequate reimbursement policies are predictable to threaten the growth of the market. There have been numerous advancements in radiology concerning imaging equipment in the recent past. Moreover, most medical insurance companies do not offer reimbursement for procedures using Computer-aided Detection (CAD). Thus, people tend to choose conventional methods for diagnosis such as biopsy, pathological tests, or conventional imaging methods such as mammography, and MRI procedures.

Breast Cancer segment is expected to be the largest during the forecast period

The breast cancer category is the largest segment in the market, due to upsurge in older women population and increase in breast cancer prevalence between the women. Moreover, the market will gain traction owing to an increase in the number of initiatives conducted by numerous groups are some of the factor foster the segment growth.

The Hospital Associated Labs segment is expected to have the highest CAGR during the forecast period

The hospitals segment accounted for the largest share of the market, owing to the increasing number of in-house diagnostic procedures performed in hospitals, the growing number of patients visiting hospitals, and rising consciousness regarding early diagnosis is the major driving factor for this market.

Region with highest share:

The North America is projected to hold the highest market share, owing to developed healthcare infrastructure, government initiatives toward public health care are expected to drive this dominance. Moreover, the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management. The additionally rising presence of numerous biotechnology as well as medical device companies, rising greater funding available for research and development projects, and high adoption of advanced technologies in this province are some of the factors driving the market growth in the province.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR, The growth is accredited to the rise in the medical tourism market, and the increase in the prevalence of cancer disease in countries of this area is favouring the market growth. The Asia Pacific is also flourishing owing to medical tourism, increasing awareness, and investment in private diagnostic centers. This is owing to the presence of a huge patient population, a well-defined regulatory system that favours fast product approvals, and the accessibility of qualified personnel at a reduced cost.

Key players in the market:

Some of the key players profiled in the Cancer Diagnostics Market include Abbott Diagnostics, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux, C.R. Bard, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (A Subsidiary of General Electric Company), Hologic,Inc, Illumina, Inc, Koninklijke Philips N.V, Qiagen, Roche Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc.

Key developments:

In July 2020: F. Hoffmann-La Roche Ltd launched the uPath PD-L1 image analysis for non-small cell lung cancer, which is an automated digital pathology algorithm.

In November 2021: Hologic, Inc. commercially launched its new Genius™ Digital Diagnostics System in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and Cervical Cancer cells in women.

In March 2021: Agilent Technologies Inc. acquired Resolution Bioscience, to reinforce its headship position in cancer diagnostics and in September 2020, Illumina, Inc. acquired GRAIL to launch a new phase of a cancer diagnosis. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosis test with the prospective to detect more cancers earlier and enable better outcomes..

Technology's Covered:

  • Instrument-Based
  • Platform-Based Diagnostics
  • Tumor Biomarkers Tests

Applications Covered:

  • Blood Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Melanoma
  • Ovarian Cancer
  • Pancreatic Cancer

End Users Covered:

  • Hospital Associated Labs
  • Diagnostic Laboratories
  • Cancer Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Diagnostics Market, By Technology

  • 5.1 Introduction
  • 5.2 Instrument-Based
    • 5.2.1 Biopsies
      • 5.2.1.1 Bone Marrow Biopsy
      • 5.2.1.2 Endoscopic Biopsy
      • 5.2.1.3 Needle Biopsy
    • 5.2.2 Liquid Biopsy
    • 5.2.3 Diagnostic Imaging
      • 5.2.3.1 Ultrasound
      • 5.2.3.2 Mammography
      • 5.2.3.3 Magnetic Resonance Imaging (MRI)
      • 5.2.3.4 Computed Tomography (CT) `
      • 5.2.3.5 Positron Emission Tomography (PET)
      • 5.2.3.5.1 Standalone Positron Emission Tomography `
      • 5.2.3.5.2 Hybrid Positron Emission Tomography
  • 5.3 Platform-Based Diagnostics
    • 5.3.1 Polymerase Chain Reaction (PCR)
    • 5.3.2 Next-Generation Sequencing (NGS)
    • 5.3.3 Microarrays
    • 5.3.4 In Situ Hybridization (ISH)
    • 5.3.5 Immunohistochemistry (IHC)
    • 5.3.6 Flow Cytometry
  • 5.4 Tumor Biomarkers Tests
    • 5.4.1 Alpha-Fetoprotein (AFP) Tests
    • 5.4.2 Alkaline Phosphatase (ALP) test
    • 5.4.3 Breast Cancer (BRCA) Gene Test
    • 5.4.4 CA-19 Tests
    • 5.4.5 Carcinoembryonic Antigen) Test
    • 5.4.6 Circulating Tumor Cell (CTC) Test
    • 5.4.7 EGFR Mutation Tests
    • 5.4.8 Human Epidermal Growth Factor Rceptor 2 (HER2)
    • 5.4.9 Kirsten Rat Sarcoma Virus (KRAS) Mutation Tests
    • 5.4.10 Prostate-Specific Antigen (PSA) Test

6 Global Cancer Diagnostics Market, By Application

  • 6.1 Introduction
  • 6.2 Blood Cancer
  • 6.3 Breast Cancer
  • 6.4 Cervical Cancer
  • 6.5 Colorectal Cancer
  • 6.6 Kidney Cancer
  • 6.7 Liver Cancer
  • 6.8 Lung Cancer
  • 6.9 Melanoma
  • 6.10 Ovarian Cancer
  • 6.11 Pancreatic Cancer

7 Global Cancer Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospital Associated Labs
  • 7.3 Diagnostic Laboratories
  • 7.4 Cancer Research Institutes

8 Global Cancer Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Diagnostics
  • 10.2 Agilent Technologies, Inc.
  • 10.3 Becton, Dickinson and Company
  • 10.4 bioMerieux
  • 10.5 C.R. Bard, Inc.
  • 10.6 F. Hoffmann-La Roche Ltd.
  • 10.7 GE Healthcare (A Subsidiary of General Electric Company)
  • 10.8 Hologic,Inc.
  • 10.9 Illumina, Inc.
  • 10.10 Koninklijke Philips N.V.
  • 10.11 Qiagen
  • 10.12 Roche Diagnostics
  • 10.13 Siemens Healthcare GmbH
  • 10.14 Thermo Fisher Scientific, Inc.